Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.74 |
| ▸ | CTSK | P43235 | 5/20 | 0.68 |
| ▸ | CTSL | P07711 | 5/20 | 0.67 |
| ▸ | CTSB | P07858 | 4/20 | 0.67 |
| ▸ | MME | P08473 | 1/20 | 0.66 |
| ▸ | ECE1 | P42892 | 1/20 | 0.66 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.66 |
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4320484 | 1.00 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL21219280 | 1.00 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL29483597 | 1.00 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL9831181 | 1.00 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL21219351 | 1.00 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL931659 | 0.95 | CAPN1 (0.69) | CAPN1CTSKCTSLCTSBMME | |
| SCHEMBL27809377 | 0.95 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSBHTRA1 | |
| SCHEMBL9828791 | 0.95 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSBHTRA1 | |
| SCHEMBL7327426 | 0.95 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSBHTRA1 | |
| SCHEMBL25406813 | 0.94 | CTSK (0.77) | CAPN1CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3521301-B1 | POLYAMIDE COMPOUND AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-11084847-B2 | Polyamide compound and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20200109166-A1 | POLYAMIDE COMPOUND AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-04-09 | — | — | US | disclosed |
| EP-3521301-A1 | POLYAMIDE COMPOUND AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2019-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084847-B2 | Polyamide compound and use thereof | OPRK1, OPRM1, OPRD1 | CAPN1 4041/4885CTSK 2207/4885CTSL 1164/4885 |
| US-20200109166-A1 | POLYAMIDE COMPOUND AND USE THEREOF | OPRK1, OPRM1, OPRD1 | CAPN1 4041/4885CTSK 2207/4885CTSL 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.